Abstract
Herr presents an excellent overview of follow-up strategy for patients with bladder cancer, including non-muscle- and muscle-invasive cancer. We should take account of balance between tumor progression and cost-benefit for follow-up of bladder cancer. The surveillance schedules followed by urologists at Graduate School of Medical Sciences Kyushu University are shown in the tables.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol. 2004;171:153–7.
Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol. 2007;177:75–9.
Tran W, Serio AM, Raj GV, Dalbagni G, Vickers AJ, Bochner BH, Herr H, Donat SM. Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. J Urol. 2008;179:96–100.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Kuroiwa, K. (2013). Urinary Bladder Carcinoma Surveillance Counterpoint: Japan. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_78
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_78
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)